The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
The current coronavirus disease 2019 (COVID-19) pandemic is the first to apply whole-
genome sequencing near to real time, with over 2 million severe acute respiratory syndrome …
genome sequencing near to real time, with over 2 million severe acute respiratory syndrome …
Antibody-mediated neutralization of SARS-CoV-2
Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
[PDF][PDF] Therapeutics and COVID-19: living guideline, 13 January 2023
World Health Organization - 2023 - apps.who.int
As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans
Animal experiments have shown that nonhuman primates, cats, ferrets, hamsters, rabbits,
and bats can be infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
and bats can be infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
C Wang, R van Haperen, J Gutiérrez-Álvarez… - Nature …, 2021 - nature.com
The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell
entry and the focus for development of protective antibodies and vaccines. Structural studies …
entry and the focus for development of protective antibodies and vaccines. Structural studies …
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
A Gharbharan, CCE Jordans… - Nature …, 2021 - nature.com
In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS …
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS …
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates
JG Liang, D Su, TZ Song, Y Zeng, W Huang… - Nature …, 2021 - nature.com
SARS-CoV-2 is the underlying cause for the COVID-19 pandemic. Like most enveloped
RNA viruses, SARS-CoV-2 uses a homotrimeric surface antigen to gain entry into host cells …
RNA viruses, SARS-CoV-2 uses a homotrimeric surface antigen to gain entry into host cells …
Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review
Y Zhu, L Sharma, D Chang - Frontiers in Immunology, 2023 - frontiersin.org
An unprecedented global pandemic caused by a novel coronavirus named SARS-CoV-2
has created a severe healthcare threat and become one of the biggest challenges to human …
has created a severe healthcare threat and become one of the biggest challenges to human …
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Abstract The coronavirus disease 2019 (COVID-19) pandemic is an exceptional public
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11
The emergence of SARS-CoV-2 antibody escape mutations highlights the urgent need for
broadly neutralizing therapeutics. We previously identified a human monoclonal antibody …
broadly neutralizing therapeutics. We previously identified a human monoclonal antibody …